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therapy. To obtain valuable data, international cooperation is 
needed. This excellent lecture was followed by comprehensive 
overviews over the German research landscape regarding 
translational research in gyneco-oncology and senology.
The award winners of the AGO TraFo meeting in May 
2013 were given time to present their latest findings during 
an oral presentation (Anna-Lena Krause (Heidelberg), best 
lecture; Melanie Kürschner (Hamburg), best poster). The 
 pre-symposium then finished with a poster presentation; the 
3 best contributions were rewarded with prizes during the 
evening’s festivities (1st prize Carolin Hülsewig (Münster), 
2nd prize Florian Bitterer (Regensburg) and 3rd prize Benjamin 
Ley (Halle)). 
COMBATing Meeting
The main meeting started with an update on recent devel-
opments since the last COMBATing in 2012. Rita Schmutzler 
(Cologne) presented the latest findings in hereditary breast 
cancer. Today’s knowledge hypothesizes the presence of 
 several not yet discovered moderate breast cancer susceptibil-
ity risk genes. Some promising candidates are currently under 
closer inspection, one of them might be the first known reces-
sive breast cancer susceptibility gene. An update on the in-
trinsic subtypes and their particular diagnostics and therapy 
was given by Cornelia Liedtke (Lübeck), focusing on the 
 significance of different predictive assays. Subsequently, 
 Alexander Katalinic (Lübeck) showed current epidemiologi-
cal data where a relevant decline in mortality in young breast 
cancer patients could be observed.
The next session focused on tumor biology and formation. 
Hans Kreipe (Hanover) gave spectacular insights into the bi-
ology of B3 lesions, whose genetic information does not differ 
much from that of invasive cancers. He demonstrated a se-
quence from B3 lesion to DCIS to invasive cancer, showing 
the high impact of this pathological finding on clinical routine. 
With the following presentation, Anette Lebeau (Lübeck) 
On November 15th–16th 2013 160 physicians, scientists, and 
students interested in breast cancer research, followed the in-
vitation of the three chairs Nadia Harbeck (Munich), Achim 
Rody (Lübeck) and Michael Gnant (Vienna) to join this 
year’s 6th COMBATing (Conference On Molecular Basics 
And Therapeutic Implications in Breast Cancer) in Lübeck. 
Recently established possibilities to gain extensive insights 
into tumor biology and genetics identify an enormous amount 
of potential targets in breast cancer therapy whose particular 
significance has to be proven in future. Therefore, this year’s 
congress focused on those new ‘Chances for Cure’ provided 
by new diagnostic techniques, e.g. next-generation sequencing. 
As usual, national and international pioneers in breast 
 cancer research shared their findings and gave an overview 
over recent topics. This unique meeting in combination with 
the AGO Trafo pre-symposium offered an outstanding plat-
form for translational networking, interdisciplinary crosstalk 
and scientific exchange for ambitious researchers, clinicians, 
pharmaceutical industry and students. 
AGO TraFo Pre-Symposium 
For the third year in a row, the main conference was 
 enriched by a pre-symposium of the AGO TraFo (Arbeits-
gruppe Gynäkologische Onkologie, Kommission Transla-
tionale Forschung), chaired by Tanja Fehm (Düsseldorf). The 
first session was set up to be a start-up aid for young research-
ers to gain ground in science. Therefore, experienced scien-
tists gave tips on project planning, financing, and statistics. In 
addition, strategies for how to write a publication and how to 
give a good presentation were shown.
Afterwards, Martin Wildschwendtner (London) held the 
TraFo keynote lecture, presenting the development of re-
search on breast cancer and gynecology in Europe. By analyz-
ing statistics on morbidity and mortality, he highlighted the 
importance of basic and translational research to gain holistic 
insights in cancerogenesis in order to improve prevention and 
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tied in perfectly, highlighting the role of stroma invasion in 
DCIS. Michael Knauer (Linz) and Marcus Schmidt (Mainz) 
discussed the common problems in clinical routine: on one 
hand ‘bad stage but good biology’and on the other hand ‘low 
stage but adverse biology’. Both speakers reasoned that only 
a combination of clinical and genetic aspects can lead to an 
appropriate prognostic estimate and therapy recommenda-
tion. Marcus Schmidt, this year’s winner of the ‘Henner 
 Graeff COMBAT Award’, concluded his talk with the wise 
citation of Karl Valentin: ‘predictions are difficult, especially 
those concerning the future’. 
The pharmaceutical industry was given the opportunity to 
present recent targets in breast cancer research. While Roche 
has products with HER3, Ang-2 and macrophages as targets 
in its pipeline, Novartis deepens its research in the mTOR/
PI3K pathway and in CDk4/6 antibodies. With these com-
pounds, phase III trials are already under way in breast 
cancer.
The first day concluded with a roundtable of the most 
 important German (GBG, AGO-B, WSG, SUCCESS, 
 DETECT), Austrian (ABCSG) and Swiss (SAKK) study 
groups. Leaders of each group presented the studies presently 
recruiting and demonstrated first results.
During the evening’s get-together, 10 travel grants were 
awarded to ambitious young researchers and the winners 
of the poster prizes were congratulated by the 3 chairs of 
COMBATing, Nadia Harbeck, Achim Rody, and Michael 
Gnant. The Henner Graeff COMBAT award 2013 was given 
to Markus Schmidt (Mainz) for his role in the development of 
several prognostic markers, such as uPA/PAI-1 or the Endo-
predict assay (fig. 1).
The second day of the meeting began with the keynote lec-
ture of Martin Widschwendtner giving insights in the clinical 
significance of epigenetics and DNA methylation. Many life 
style factors can lead to epigenetic misprograming leading to 
cancerogenesis. Especially methylation of CpG-islands and 
the repression of polycomb group proteins in stem cells may 
play a crucial role. Epigenetic methylation in BRCA1/2-muta-
tion carriers causes elevated progesterone serum levels and an 
up-regulation of RANK-ligand leading to a higher individual 
risk in developing cancer. This knowledge may be used in pre-
vention in the future.
The next session gave insight into the biology of the tumor 
cell. Illuminating the mTOR/PI3K pathway Friedrich Over-
kamp (Recklinghausen) showed the main reasons for endo-
crine resistance (PTEN loss, PI3K mutation or amplification) 
and ways to overcome them. Unfortunately, there are no vali-
dated biomarkers for products in the pipeline yet. A new 
drug, BKM 120, a pan-class PI3K inhibitor, is a promising 
substance with the ability to pass the blood-brain barrier. But 
a new spectrum of adverse effects may be problematic and 
 require proactive management and patient education. Oleg 
Gluz (Mönchengladbach) highlighted the special role of 
HER2 in cancerogenesis and metastasis of breast cancer in an 
engaging speech. He pointed out that a prognostic differentia-
tion between HER2-positive, hormone receptor-negative and 
triple-positive breast cancer is essential. In his presentation 
about tumor-stromal interactions, Thomas Karn (Frankfurt/
Main) focused on tumor infiltrating lymphocytes, which may 
play a role in chemo-response of triple negative breast cancer 
(TNBC). He demonstrated the wide complexity of the im-
mune response in cancer and outlined possible therapeutic 
approaches.
Subtype-specific patterns of metastasis in breast cancer 
were the focus of Rachel Würstlein (Munich), showing that 
a better prediction of the location of metastases will be possi-
ble in future, which may help to establish better detection 
and even prevention. The best approach for therapy recom-
mendation is still to consider the biology of primary and 
 metastatic disease and the observed response to prior treat-
ment. Volker Müller (Hamburg) concentrated on brain me-
tastases, whose incidence is increasing. As data are largely 
lacking, a special data and tissue register will be established 
(www.germanbreastgroup.de). The aim is to identify patients 
with a high risk of developing brain metastases who may ben-
efit from special early detection programs or even from pre-
ventive irradiation. Actinotherapeutic aspects of breast can-
cer research were shown by Jochen Fleckstein (Homburg/
Saar). Hypofractionation of irradiation is a budding therapy 
option; also the parallel use of substances affecting DNA 
 repair, such as platinum derivatives and PARP-inhibitors is 
promising.
In his brilliant lecture Peter Fasching (Erlangen) showed 
the enormous amount of data which is obtained by gene 
 profiling of breast cancer tissue. At the moment, the biggest 
Fig. 1. The chairs Achim Rody, Michael Gnant and Nadia Harbeck 
(from left to right) award the Henner Graeff-COMBAT award to Martin 
Schmidt (3rd from left) accompanied by his laudator Christoph Thomssen 
(Halle) and Sigrid Welte (Novartis, sponsor of the award).
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challenge for the clinician is the confrontation with this huge 
amount of information and a lack of specific therapy. The 
 impact of metformin and statins as therapeutic approaches in 
breast cancer was discussed by Brigitte Rack (Munich), show-
ing that especially biguanide has a positive effect on risk re-
duction in cancer in general. However, it might be hypothe-
sized that a lifestyle intervention may lead to the same effect. 
Afterwards, an update on the role of vitamin D in breast 
 cancer therapy was presented by Marc Till (Frankfurt/Main). 
He revealed that there is still no evidence of a benefit from 
vitamin D therapy. Therefore, a strict recommendation does 
not exist.
In the next session, special clinical constellations were re-
viewed. Dorothea Fischer (Lübeck) presented the case of 
young breast cancer patients. Here, a more aggressive biology 
is observed and the clinician is disproportionally often con-
fronted with hereditary or pregnancy associated breast can-
cer. Breast cancer in elderly patients was discussed by Hans-
Joachim Lück (Hanover). In spite of a better biology, a 
poorer prognosis is observed due to non-standard therapy. 
Finally, Sibylle Loibl (Neu-Isenburg) gave an exciting update 
on pregnancy associated breast cancer and fertility after 
breast cancer. To gain better insights into this special issue, 
all participants were encouraged to introduce pregnant 
breast cancer patients in the recruiting GBG register study 
(www.germanbreastgroup.de).
Conclusion
This 6th COMBATing meeting with AGO TraFo pre- 
symposium in Lübeck was an outstanding success. The excel-
lent choice of national and international speakers discussing 
recent topics made this event unique. Researchers and clini-
cians from Germany, Austria, and Switzerland were given a 
possibility for networking and scientific exchange without 
comparison. 
This year’s meeting showed the advancement in breast can-
cer from an unselective ‘one size fits all’ approach to identifi-
cation of the right individualized therapy for the right patient. 
We are all looking forward to learn more about these devel-
opments and happily accept the invitation of the chairpersons 
Michael Gnant, Achim Rody, and Nadia Harbeck to the 7th 
COMBATing in Düsseldorf, November 21–22, 2014.
More information about the meeting can be found at 
www.combating.de.
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